Since PD-L1 tumor staining by immunohistochemical is routinely used as an immunotherapy biomarker in multiple cancer types including NSCLC, further studies to investigate the relationship between BRGPs signature and PD-L1 expression are urgently warranted both in the mRNA and protein levels. This evidence concerns the gene CD274 and non-small cell lung carcinoma.